Patents Assigned to Cymabay Therapeutics, Inc.
  • Treatment of NAFLD and NASH
    Patent number: 9962346
    Abstract: Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: May 8, 2018
    Assignee: CymaBay Therapeutics, Inc.
    Inventors: Brian Roberts, Xueyan Wang, Yun-Jung Choi, David Karpf, Robert Martin, Charles McWherter
  • Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
    Patent number: 9925189
    Abstract: Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control. The compounds of the invention are orally active.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: March 27, 2018
    Assignee: CYMABAY THERAPEUTICS, INC.
    Inventors: Xin Chen, Peng Cheng, L. Edward Clemens, Jeffrey D. Johnson, Jingyuan Ma, Alison Murphy, Imad Nashashibi, Christopher J. Rabbat, Jiangao Song, Maria E. Wilson, Yan Zhu, Zuchun Zhao
  • Methods for Treating Gout Flares
    Publication number: 20180055803
    Abstract: Methods of treating gout flares comprising administering a composition comprising a first urate-lowering agent are disclosed. In some aspects, the first urate-lowering agent is (?)-halofenate, (?)-halofenic acid, or a pharmaceutically acceptable salt thereof. Other aspects provide for methods of reducing the number, duration, frequency or intensity of gout flares experienced by a subject.
    Type: Application
    Filed: November 2, 2015
    Publication date: March 1, 2018
    Applicant: CymaBay Therapeutics, Inc.
    Inventors: Brian Edward Lavan, Gopal Chandra Saha, Brian K. Roberts, Charles A. McWherter
  • Treatment of intrahepatic cholestatic diseases
    Publication number: 20180036268
    Abstract: Treatment of intrahepatic cholestatic diseases by therapy with MBX-8025 or an MBX-8025 salt.
    Type: Application
    Filed: September 29, 2017
    Publication date: February 8, 2018
    Applicant: CymaBay Therapeutics, Inc.
    Inventors: Pol Boudes, Charles A. McWherter
  • Treatment of NAFLD and NASH
    Publication number: 20180008566
    Abstract: Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.
    Type: Application
    Filed: March 2, 2017
    Publication date: January 11, 2018
    Applicant: CymaBay Therapeutics, Inc.
    Inventors: Brian Roberts, Xueyan Wang, Yun-Jung Choi, David Karpf, Robert Martin, Charles McWherter
  • Crystalline solid and amorphous forms of (?)-halofenate and methods related thereto
    Patent number: 9845285
    Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: December 19, 2017
    Assignees: CymaBay Therapeutics, Inc., DiaTex, Inc.
    Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
  • Treatment of intrahepatic cholestatic diseases
    Patent number: 9808436
    Abstract: Treatment of intrahepatic cholestatic diseases by therapy with MBX-8025 or an MBX-8025 salt.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: November 7, 2017
    Assignee: CymaBay Therapeutics, Inc.
    Inventors: Pol Boudes, Charles A. McWherter
  • Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
    Patent number: 9801860
    Abstract: Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering agent and a second urate-lowering agent. In some aspects the first urate-lowering agent is (?)-halofenate, (?)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second urate-lowering agent is an inhibitor of uric acid production, a uricosuric agent, a uricase, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: October 31, 2017
    Assignees: CymaBay Therapeutics, Inc., DiaTex, Inc.
    Inventors: Brian K. Roberts, Gopal Chandra Saha, Brian Edward Lavan, Charles A. McWherter
  • Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
    Patent number: 9737537
    Abstract: Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control. The compounds of the invention are orally active.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: August 22, 2017
    Assignee: CYMABAY THERAPEUTICS, INC.
    Inventors: Xin Chen, Peng Cheng, L. Edward Clemens, Jeffrey D. Johnson, Jingyuan Ma, Alison Murphy, Imad Nashashibi, Christopher J. Rabbat, Jiangao Song, Maria E. Wilson, Yan Zhu, Zuchun Zhao
  • Treatment of NAFLD and NASH
    Patent number: 9616039
    Abstract: Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: April 11, 2017
    Assignee: CYMABAY THERAPEUTICS, INC.
    Inventors: Brian Roberts, Xueyan Wang, Yun-Jung Choi, David Karpf, Robert Martin, Charles McWherter
  • Bicyclic agonists of GPR131 and uses thereof
    Patent number: 9593109
    Abstract: The present disclosure relates to compounds that act as agonists of, or otherwise modulate the activity of, GPR131 and to their use in the treatment of various diseases. In particular embodiments, the structure of the compounds is given by Formula I: wherein the variables are as described herein. Related compositions, formulations and methods for the preparation of compounds of formula I are also described.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: March 14, 2017
    Assignee: CYMABAY THERAPEUTICS, INC.
    Inventors: Jiangao Song, Phuongly Pham, Jingyuan Ma, Aaron Robert Novack, Imad Nashashibi, David W. G. Wone, Dong-Fang Shi, Xin Chen
  • Treatment of intrahepatic cholestatic diseases
    Publication number: 20170014363
    Abstract: Treatment of intrahepatic cholestatic diseases by therapy with MBX-8025 or an MBX-8025 salt.
    Type: Application
    Filed: September 21, 2016
    Publication date: January 19, 2017
    Applicant: CymaBay Therapeutics, Inc.
    Inventors: Pol Boudes, Charles A. McWherter
  • METHODS OF REDUCING SMALL, DENSE LDL PARTICLES
    Publication number: 20160324811
    Abstract: The present invention provides methods for increasing LDL particle size.
    Type: Application
    Filed: January 13, 2016
    Publication date: November 10, 2016
    Applicant: CymaBay Therapeutics, Inc.
    Inventors: David Karpf, Ronald M. Krauss, Yun-Jung Choi, Xueyan Wang, Francine M. Gregoire
  • Treatment of NAFLD and NASH
    Publication number: 20160324812
    Abstract: Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.
    Type: Application
    Filed: June 2, 2016
    Publication date: November 10, 2016
    Applicant: CymaBay Therapeutics, Inc.
    Inventors: Brian Roberts, Xueyan Wang, Yun-Jung Choi, David Karpf, Robert Martin, Charles McWherter
  • Treatment of intrahepatic cholestatic diseases
    Patent number: 9486428
    Abstract: Treatment of intrahepatic cholestatic diseases by therapy with MBX-8025 or an MBX-8025 salt.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: November 8, 2016
    Assignee: CymaBay Therapeutics, Inc.
    Inventors: Pol Boudes, Charles A. McWherter
  • Treatment of Severe Hyperlipidemia
    Publication number: 20160279085
    Abstract: Treatment of severe hyperlipidemia by administration of (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid or a salt thereof in combination with a PCSK9 inhibitor.
    Type: Application
    Filed: May 19, 2016
    Publication date: September 29, 2016
    Applicant: CymaBay Therapeutics, Inc.
    Inventors: Robert L. Martin, Charles A. McWherter, Patrick J. O'Mara
  • Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
    Publication number: 20160271111
    Abstract: Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering agent and a second urate-lowering agent. In some aspects the first urate-lowering agent is (?)-halofenate, (?)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second urate-lowering agent is an inhibitor of uric acid production, a uricosuric agent, a uricase, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 18, 2015
    Publication date: September 22, 2016
    Applicant: CymaBay Therapeutics, Inc.
    Inventors: Brian K. Roberts, Gopal Chandra SAHA, Brian Edward LAVAN, Charles A. McWHERTER
  • Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
    Patent number: 9439891
    Abstract: Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering agent and a second urate-lowering agent. In some aspects the first urate-lowering agent is (?)-halofenate, (?)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second urate-lowering agent is an inhibitor of uric acid production, a uricosuric agent, a uricase, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: September 13, 2016
    Assignees: CymaBay Therapeutics, Inc., DiaTex, Inc.
    Inventors: Brian K. Roberts, Gopal Chandra Saha, Brian Edward Lavan, Charles A. McWherter
  • Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
    Patent number: 9433612
    Abstract: Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering agent and a second urate-lowering agent. In some aspects the first urate-lowering agent is (?)-halofenate, (?)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second urate-lowering agent is an inhibitor of uric acid production, a uricosuric agent, a uricase, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: September 6, 2016
    Assignees: CymaBay Therapeutics, Inc., DiaTex, Inc.
    Inventors: Brian K. Roberts, Gopal Chandra Saha, Brian Edward Lavan, Charles A. McWherter
  • Treatment of NAFLD and NASH
    Patent number: 9381181
    Abstract: Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: July 5, 2016
    Assignee: CymaBay Therapeutics, Inc.
    Inventors: Brian Roberts, Xueyan Wang, Yun-Jung Choi, David Karpf, Robert Martin, Charles McWherter